News
SHPHF
0.235
NaN%
--
Sihuan Pharmaceutical’s Xuanzhu Biopharma Plans H Share Full Circulation
TipRanks · 11/18 15:09
Sihuan Pharmaceutical Partners with Abalone Bio for Innovative Obesity Therapy
TipRanks · 10/30 00:09
Sihuan Pharmaceutical Announces Strategic Share Repurchase Amidst Strong Business Growth
TipRanks · 10/17 13:12
Sihuan Pharmaceutical Strengthens Market Position with Share Purchase
Barchart · 10/16 04:50
Sihuan Pharmaceutical Successfully Lists Xuanzhu Biopharm on Hong Kong Stock Exchange
Barchart · 10/15 23:14
Sihuan Pharmaceutical Announces Strategic Share Repurchase Amidst Business Growth
TipRanks · 10/15 11:39
Sihuan Pharmaceutical Enhances Share Award Scheme with Strategic Share Purchase
Barchart · 10/13 23:14
Sihuan Pharmaceutical Expands Global Reach with Suisselle Investment
Barchart · 10/13 19:14
Sihuan Pharmaceutical Announces Spin-off and Listing of Xuanzhu Biopharm
Barchart · 10/07 05:52
Sihuan Pharmaceutical’s Meiyan Space Gains Approval for New Skin Booster Product
TipRanks · 09/30 08:44
Sihuan Pharmaceutical Announces Strategic Share Repurchase and Product Launches
TipRanks · 09/26 12:11
Sihuan Pharmaceutical’s Subsidiary Xuanzhu Biopharm Moves Closer to Hong Kong Listing
TipRanks · 09/17 15:11
Sihuan Pharmaceutical Announces Shareholder Entitlement for Xuanzhu Biopharm Spin-Off
TipRanks · 09/17 15:11
Weekly Report: what happened at SHPHF last week (0908-0912)?
Weekly Report · 09/15 11:10
Sihuan Pharmaceutical’s Subsidiary Gains Approval for Innovative Diabetes Drug
TipRanks · 09/09 00:09
More
Webull provides a variety of real-time SHPHF stock news. You can receive the latest news about Sihuan Pharm Hld through multiple platforms. This information may help you make smarter investment decisions.
About SHPHF
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company primarily engaged in the research and development, manufacture and sale of pharmaceutical products and aesthetic products. The Company operates its business through three segments. The Medical Aesthetic Products segment includes the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skin care and others to provide non- or minimally invasive medical aesthetic comprehensive solutions. The Innovative Medicine and Other Medicine segment is engaged in the research and development and commercialization of innovative medicine in the disease fields of diabetes, breast cancer, digestion disorders, oncology and non-alcoholic steatohepatitis and others. The Generic Medicine segment is engaged in the production and sale of generic medicine including Kelin’ao and other products. The Company conducts its business in the domestic and overseas markets.